department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

News

when

Latest
Archive

by source

All Sources
Sources Page

Companies

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

Calendar

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

made by humans and a good dog

home
jobs
news
cal
search

calendar

17 catalysts · 18,987 approval · 5,000 device 510k · 4,728 grant · 3,921 phase readout · 2,141 8k filing · 2,000 device pma

★ save view ↓export CSV

next 91 dayslessmore

MonWedFri

view

agenda month

hide past →

sort

soonest latest type sponsor alpha

type: filing×type: patent expiry×clear all

type

approval18,987
device 510k5,000
grant4,728
phase readout3,921
8k filing2,141
device pma2,000

device recall

2,000

recall1,126

device adverse event1,000

earnings284

therapy area

Infectious Disease9
Ophthalmology5
Oncology2
Dermatology1
Pulmonology1

Week of Apr 20, 2026

›Apr 24, 2026patent expiry80d agoDaiichi Sankyo Co Ltd — laninamivir (Constraining Patent Expiry (Japan))laninamivir

Therapy area: Infectious Disease, Respiratory. Indication: Asthma, Influenzavirus A Infections, Influenzavirus B Infections

full page →laninamivir →source: globaldata

›Apr 24, 2026patent expiry80d agoEisai Co Ltd — lenvatinib mesylate (Constraining Patent Expiry (US))lenvatinib mesylate

Therapy area: Gastrointestinal, Infectious Disease, Oncology. Indication: Acral Lentiginous Melanoma, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Thyroid Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Endometrial Cancer, Ependymoma, Epithelial Ovarian Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Ewing S

full page →lenvatinib mesylate →source: globaldata

›Apr 25, 2026patent expiry79d agoStemline Therapeutics Inc — SL-901 (Constraining Patent Expiry (Japan))SL-901

Therapy area: Oncology, Undisclosed. Indication: Lung Cancer, Solid Tumor, Unspecified Rare Disease

full page →SL-901 →source: globaldata

›Apr 26, 2026patent expiry78d agoBlue Blood Biotech Corp — BB-101 (Constraining Patent Expiry (Japan))BB-101

Therapy area: Dermatology. Indication: Diabetic Foot Ulcers

full page →BB-101 →source: globaldata

Week of Apr 27, 2026

›Apr 27, 2026patent expiry77d agoBill & Melinda Gates Medical Research Institute — SB-692342 (Constraining Patent Expiry (Japan))SB-692342

Therapy area: Infectious Disease. Indication: Pulmonary Tuberculosis

full page →SB-692342 →source: globaldata

›Apr 28, 2026patent expiry

76d ago

GSK plc — dolutegravir sodium ODT (Constraining Patent Expiry (Japan))dolutegravir sodium

Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

full page →dolutegravir sodium →source: globaldata

›Apr 28, 2026patent expiry76d agoGSK plc — (abacavir sulfate + dolutegravir sodium+ lamivudine) ODT (Constraining Patent Expiry (Japan))(abacavir sulfate + dolutegravir sodium + lamivudine)

Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

full page →(abacavir sulfate + dolutegravir sodium + lamivudine) →source: globaldata

›Apr 28, 2026patent expiry76d agoGSK plc — cabotegravir sodium (Constraining Patent Expiry (US))cabotegravir sodium

Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

full page →cabotegravir sodium →source: globaldata

›Apr 28, 2026patent expiry76d agoViiV Healthcare UK Ltd — cabotegravir + rilpivirine LA (Constraining Patent Expiry (US))cabotegravir + rilpivirine LA

Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

full page →cabotegravir + rilpivirine LA →source: globaldata

›Apr 28, 2026patent expiry76d agoViiV Healthcare UK Ltd — cabotegravir LA (Constraining Patent Expiry (US))cabotegravir LA

Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

full page →cabotegravir LA →source: globaldata

›Apr 30, 2026patent expiry74d agoBasilea Pharmaceutica Ltd — isavuconazonium sulfate (Constraining Patent Expiry (US))isavuconazonium sulfate

Therapy area: Infectious Disease. Indication: Aspergillosis, Candidiasis, Cryptococcal Meningitis, Cryptococcosis, Zygomycosis (Mucormycosis)

full page →isavuconazonium sulfate →source: globaldata